undamentalytics Newsletter
Sign in

Edgewise Therapeutics, Inc. (EWTX) stock

Add to watchlist

Add holding +

NASDAQ: EWTX Nasdaq Biotechnology Next results ~November 5, 2026

Edgewise Therapeutics, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders1 buying, 6 selling1 purchase and 33 sales by directors and officers, last 12 monthsInsider trades
  • Funds121 adding, 99 cuttingOf 45 active managers that changed their stake, 22 added; quarter to June 30, 2026Fund buyers and sellers

The Fundamentalytics view

Next results ~November 5, 2026 (estimated)

Current signal Results well short of expectations: Reported earnings per share missed the analysts' consensus estimate by 12% in the quarter to 2026-06-30.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

Nothing in Edgewise Therapeutics, Inc.'s latest figures clears our strength thresholds.

Things to watch

  • Results due soon. Results are expected around 5 November; the share price can move sharply on the day.
  • Volatile shares. Over the past year the shares showed annualised volatility of 73% and a beta of 1.4 against the S&P 500.
  • Heavily shorted. 15.2% of the shares available to trade are sold short (6.6 days of average volume to cover).
  • Missing expectations. Earnings per share fell short of the consensus estimate in 2 of the last four quarters.

Latest results

Earnings per share
-$0.53 against an average estimate of -$0.47: missed by 12.2%
Share reaction
-3.3% in the first session after the results on August 6, 2026, against +0.5% for the S&P 500
Next report
November 5, 2026; average EPS estimate $2.51

Edgewise Therapeutics' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-2.0%
  • 1 week-2.7%
  • 1 month-7.9%
  • This year+53.6%
  • 1 year+108.5%
  • 5 years+97.7%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Earnings

Last results
August 6, 2026
Next results (est.)
November 5, 2026

News & updates

Updated November 2, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Announcement
  2. Results
  3. Deal

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Edgewise Therapeutics, Inc. valuation models and calculator

No model value for Edgewise Therapeutics, Inc. at the moment. Current status: limited reported history: available models are shown without a Buy/Hold/Sell rating. Available reported financials are shown below.

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: limited reported history: available models are shown without a Buy/Hold/Sell rating.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 5, 2026, before the open. Analysts expect revenue of $119m and EPS of $2.51 (range −$0.64 to $11.45) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current $2.27 +240% $129m 0%
Next −$1.77 −178% $39m −70%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is −1070.8% on 90 days ago. In the last 30 days, 0 analysts raised Edgewise Therapeutics, Inc.'s forecast and 5 cut it.

Consensus EPS forecast Edgewise Therapeutics, Inc., last 90 days
−$2.00 $0.00 $2.00 $4.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$0.23 Current fiscal year, 60 days ago: $1.38 Current fiscal year, 30 days ago: $1.38 Current fiscal year, 7 days ago: $2.27 Current fiscal year, Now: $2.27 $2.27 Next fiscal year, 90 days ago: −$1.47 Next fiscal year, 60 days ago: −$1.82 Next fiscal year, 30 days ago: −$1.82 Next fiscal year, 7 days ago: −$1.77 Next fiscal year, Now: −$1.77 −$1.77

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$0.23−$1.47
60 days ago $1.38−$1.82
30 days ago $1.38−$1.82
7 days ago $2.27−$1.77
Now $2.27−$1.77

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.47 −$0.53 −12.2%
Mar 2026 −$0.48 −$0.46 +5.1%
Dec 2025 −$0.44 −$0.47 −6.2%
Sept 2025 −$0.40 −$0.39 +2.8%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

14 analysts, Oct 2026
Buy1286%
Hold214%
Sell00%

Monthly trend

  1. Oct 202639214
  2. Sep 202638213
  3. Aug 202638213
  4. Jul 202638213

Counts of recommendations published by analysts covering Edgewise Therapeutics, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
15.3%
of tradable shares
Days to cover
6.61
at average volume
Short interest, 1 month
+23%
to October 15, 2026
Held by institutions
—
of shares
Held by insiders
0.5%
of shares
Employees
127
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Return and risk by year

Calendar year 20222023202420252026 to date
Return
EWTX−42%+22%+144%−7%+54%
Industry peers (median)−57%−18%−29%−5%−27%
S&P 500−18%+26%+25%+18%+11%
Months that ended higher
EWTX25%42%50%50%55%
S&P 50042%67%75%75%46%
Largest fall from a high during the year
EWTX−70%−51%−31%−62%−25%
S&P 500−25%−10%−8%−19%−9%

Worst fall since March 26, 2021: 85% from March 29, 2021 to November 10, 2023. Getting back needed a 553% gain, reached on November 6, 2024, 362 days after the low.

Price behaviour

52-week range
$17.09 – $48.35
From 52-week high
−21.2%
vs 50-day average
−7.5%
vs 200-day average
+4.9%
Volatility (1 year)
73%
Beta vs S&P 500
1.36

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
4 up, 8 down
typical move ±8.5%
After a week
5 up, 7 down
typical move ±13.6%
After a month
6 up, 6 down
typical move ±18.4%
Results releasedNext dayS&P 500 next day5 days21 days
August 6, 2026 −3.3% +0.5% −4.0% −4.3%
May 7, 2026 −4.5% +0.5% −8.1% −5.8%
February 26, 2026 +1.1% −1.0% −5.7% +2.4%
November 6, 2025 −1.2% −1.0% +17.6% +35.6%
August 7, 2025 −6.2% +0.7% +3.1% +10.1%
May 8, 2025 +0.4% +0.6% −0.5% +5.1%
March 3, 2025 −6.4% −2.9% +5.2% −23.1%
November 7, 2024 −0.7% +1.2% −10.2% −17.4%
August 8, 2024 +3.6% +2.8% +18.8% +10.8%
May 9, 2024 −12.3% +0.7% −13.0% −18.0%
February 22, 2024 −1.3% +2.1% −6.7% −7.1%
January 19, 2024 +60.5% +1.5% +70.5% +81.3%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Fundamentals

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms . Generated November 3, 2026. Definitions in our methodology.

Who owns it

Funds buying and selling
Reported value
$4.8B
Institutions reporting
224
Shares held vs prior quarter
▲ 0.3%
Positions opened / closed
39 / 26

Top buyers and sellers, Q2 2026: 121 institutions bought and 99 sold ; the biggest buyer was FMR LLC (+4.5M shares) and the biggest seller Baker Bros. Advisors LP (−2.9M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Orbimed Advisors LLC $631M 15.5M 13.1% 0.0%
Paradigm Biocapital Advisors LP $415M 10.2M 8.6% ▲ 38.7%
RA Capital Management, L.P. $341M 8.4M 7.1% ▼ 19.5%
Blackrock, Inc. $268M 6.6M 5.6% ▲ 2.1%
Jupiter Topco LLC $247M 6.1M 5.1% —
FMR LLC $223M 5.5M 4.6% ▲ 439.7%
Novo Holdings A/S $217M 5.3M 4.5% 0.0%
Driehaus Capital Management LLC $192M 4.7M 4.0% ▲ 5.6%
Perceptive Advisors LLC $178M 4.4M 3.7% ▼ 1.1%
Vanguard Capital Management LLC $157M 3.9M 3.3% ▲ 1.9%
Baker Bros. Advisors LP $150M 3.7M 3.1% ▼ 43.7%
Siren, L.L.C. $129M 3.2M 2.7% ▼ 28.1%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Edgewise Therapeutics, Inc.'s complete shareholder register. Values are as reported by the filers ; 2 inconsistently scaled filing rows were excluded.

Insider trading activity

Full insider history and chart
Insider purchases History → $199,448 1 trade by 1 insider, last 12 months Insider sales History → $19.5M 33 trades by 6 insiders · 82% under pre-set plans
Net ▼ $19.3M net selling
Insider Date Trade Shares Price Value
Donovan Joanne M. CMO August 13, 2026 Sell pre-set plan 2,919 $43.41 $126,714
Koch Kevin President and CEO August 12, 2026 Sell 913 $44.33 $40,473
Koch Kevin President and CEO August 12, 2026 Sell 8,782 $43.64 $383,246
Koch Kevin President and CEO August 12, 2026 Sell 8,276 $43.66 $361,330
Derakhshan Behrad Chief Business Officer August 12, 2026 Sell 2,171 $43.79 $95,068
Derakhshan Behrad Chief Business Officer August 12, 2026 Sell 304 $44.50 $13,528
Derakhshan Behrad Chief Business Officer August 12, 2026 Sell 2,475 $43.70 $108,158
Derakhshan Behrad Chief Business Officer August 12, 2026 Sell 150 $44.44 $6,666
Moore John R General Counsel August 12, 2026 Sell 2,419 $43.80 $105,952
Moore John R General Counsel August 12, 2026 Sell 99 $44.50 $4,406
Moore John R General Counsel August 12, 2026 Sell 59 $44.41 $2,620
Moore John R General Counsel August 12, 2026 Sell 2,439 $43.81 $106,853

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around November 5, 2026 estimated from the company's past filing pattern, not announced

  • August 6, 2026
  • May 7, 2026
  • February 26, 2026
  • November 6, 2025
  • August 7, 2025
  • May 8, 2025

Recent SEC filings

Data status

When each part of this page on Edgewise Therapeutics, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Edgewise Therapeutics, Inc. in brief

What does Edgewise Therapeutics, Inc. do?
Edgewise Therapeutics, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Edgewise Therapeutics, Inc.'s stock ticker?
Edgewise Therapeutics, Inc. trades under the ticker EWTX on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
Who are Edgewise Therapeutics, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Orbimed Advisors LLC, Paradigm Biocapital Advisors LP and RA Capital Management, L.P. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
Are insiders buying or selling Edgewise Therapeutics, Inc. stock?
Over the last 12 months, Edgewise Therapeutics, Inc.'s directors and officers reported 1 open-market purchases and 33 sales on Form 4. The insider trading page charts every trade.
When is Edgewise Therapeutics, Inc.'s next earnings date?
Around November 5, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Edgewise Therapeutics, Inc. announces its own schedule.